Following a lawsuit filed last week, Sage has officially rejected Biogen’s unsolicited buyout offer, which valued the ...

After receiving and considering an "unsolicited" buyout offer from partner Biogen, Sage Therapeutics is kicking the tires on a range of strategic options. | The company's board of directors ...

Since then, Biogen decided to opt out of their partnership on essential tremor candidate SAGE-324 after disappointing results ...

The proposed merger of the two Cambridge drugmakers is off, but Sage says it's open to "strategic alternatives" — including a sale. Sage Therapeutics Inc. is looking for a deal — but it’s ...

Business Insider's personal finance team compared Sage Mortgage to the best mortgage lenders and found it to be a standard lender Sage Mortgage has loan options that should meet most borrowers ...

Barclays analyst Sven Merkt maintained a Sell rating on Sage Group plc (SGE – Research Report) today and set a price target of £10.80. The ...

Sage Therapeutics (SAGE) announced that its board of directors has initiated a process to explore strategic alternatives for the company. The ...

AUSTIN, Texas--(BUSINESS WIRE)--Blue Sage Capital, a leading lower-middle market private equity firm, today announced the final close of Blue Sage Capital IV, L.P. (the “Fund”), at $618 ...

(Reuters) -Britain's Sage Group on Thursday maintained its revenue forecast for fiscal 2025 after the software firm posted 10% growth in first-quarter underlying revenue, driven by higher demand, ...